Clinical Outcomes And Safety Profile Of Standalone Canaloplasty Vs. Canaloplasty Combined With Cataract Surgery Using Itrack Microcatheter

To evaluate the clinical outcomes and safety profile of standalone ab-interno canaloplasty performed using the iTrack microcatheter (Nova Eye Medical) compared to ab-interno canaloplasty combined with cataract surgery.

Multicenter cloud-based database (iTGDR, part of the International Glaucoma Surgery Registry – IGSR)

Prospective data collected from the database, including eyes with glaucoma diagnosis and 12 months of follow-up. Patients underwent canaloplasty using the ab-interno technique with the iTrack or iTrack Advance (Nova Eye Inc., Fremont, USA), either as a standalone procedure (standalone group) or combined with cataract surgery (+phaco group). Success was defined as IOP reduction ≥20% or more compared to baseline and no increase in medication use or IOP ≤18 mmHg with no medications.

A total of 281 eyes were followed for a mean of 21.8±7.7 months. In the standalone group (24 eyes: 18 phakic, 6 pseudophakic), mean baseline IOP and medication use decreased significantly from 20.1±7.3 mmHg and 2.3±0.9 medications to 15.3±6.4 mmHg (p=0.010) and 1.4±1.5 medications (p<0.001). In the +phaco group (257 eyes), IOP and medication use were significantly reduced from 17.4±5.4 mmHg and 2.1±1.2 medications at baseline to 14.2±4 mmHg and 1.3±1.4 medications at postop (p<0.001 for both). Success was achieved in 54% of standalone eyes and 62% of +phaco eyes. No serious adverse events were reported.

Both standalone canaloplasty and canaloplasty combined with cataract surgery using the iTrack microcatheter significantly reduced intraocular pressure and the number of medications, with no serious adverse events observed.